ABEC Releases 4000-L Single-Use Bioreactor
ABEC increases the maximum capacity of its Custom Single Run Bioreactors to 4000 L, doubling the industry standard.
ABEC, a provider of integrated solutions and services for biopharmaceutical manufacturing, announced on July 10, 2017 the release of single-use bioreactors with production volumes of 4000 L. The company reports that it is the only supplier able to provide single-use bioreactors with capacities greater than 2000 L.
The 4000-L capability enables a reduction in capital, facility, and disposables cost by doubling cell culture capacity in approximately the same floor space. The number of systems and disposable containers needed is cut in half, and facility size is reduced.
The 4000-L CSR Bioreactor has demonstrated performance comparable to stainless steel systems, a key feature of the company’s Custom Single Run (CSR) product line. Features of the line include large production volumes, performance comparable to stainless steel systems, seamless process transfer and scale-up, rapid container loading, and a non-proprietary supply chain, the company reports.
Source: ABEC
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Pharmaceutical Tariffs Are Imminent: How Industry is Bracing for Impact
April 16th 2025On April 14, 2025, the Trump Administration launched a national security-driven investigation into pharmaceuticals, a move that will likely result in tariffs being placed on pharmaceutical drugs, ingredients, and other components that are imported from outside of the United States.
